About InterRad Medical
InterRad Medical is developing a catheter anchoring device called SecurAcath Catheter Retention System. The SecurAcath System is a new and method for holding catheters in place over and extended time. The SecurAcath System aims to utilize a very small anchor that deploys just under the skin to hold a catheter securely in place.
InterRad Medical Patents
InterRad Medical has filed 110 patents.
Actuators, Valves, Medical equipment, Surgical instruments, Engine technology
Actuators, Valves, Medical equipment, Surgical instruments, Engine technology
Latest InterRad Medical News
Aug 26, 2023
The largest study of patients with peripherally inserted central catheters (PICC) utilizing a subcutaneous anchoring securement system (SASS) ever conducted shows that using subcutaneous anchors to secure catheters is more effective than using adhesive securement devices (ASD). The retrospective study was conducted at The Clatterbridge Cancer Centre in England and published in the Journal of Vascular Access on August 1, 2023. It compared the outcomes of using different securement systems in more than 9,200 oncology patients, covering more than a million catheter days, from 2009 to 2020. A significant outcome of the study found that adhesives devices, such as Stat-Lock or Grip-Lock, put patients at 36 times greater risk of partial or complete dislodgement of their PICC compared to a subcutaneous anchor, such as SecurAcath®. The results were clear and impressive, say co-authors Carol McCormick, RN, MSc, BSc (Hons), Clinical Interventions Lead Nurse at The Clatterbridge Cancer Centre UK, and Michelle Hawes, DNP, CRNI, VA-BC, ACRP-CP President of the Association for Vascular Access Foundation. Twelve percent of patients with catheters held in place with adhesives required unplanned catheter replacements, compared to only 0.4% of patients with SecurAcath. Prior to the implementation of SASS only 77% of the oncology patients made it to the end of need for their PICC without a replacement required. By 2020, 99% of the patients with a SecurAcath holding their PICC finished their course of need with one catheter. "Based on the evidence, the best instrument for securing a catheter throughout a patient's therapeutic need is the subcutaneous anchoring securement device," says Hawes. The study suggests that switching to SecurAcath can both improve patient outcomes and reduce overall healthcare costs. Thousands of central venous access devices (CVADs), including central venous catheters (CVCs) and PICCs, are inserted into patients every month. In cancer patients, for example, catheters are used to deliver treatments or nutrition, or to retrieve blood samples. Failing to properly secure these catheters can delay vital chemotherapy, testing, or increase the chances of complications such as catheter-related bloodstream infections, thrombus, dislodgement and catheter occlusion. Historically, the standard medical practice has been to secure most central venous catheters with sutures and most PICCs with an ASD. While a SASS, commercially available as SecurAcath in 38 countries, developed and patented by Interrad Medical and supplied through Eloquest Healthcare, Inc., in the US, has been available for nearly two decades, many health professionals are not familiar with its use. Related Stories When McCormick first introduced SecurAcath to Clatterbridge, "the majority of nurses were fearful of the device," she recalls. Since then, its use has grown. As the only subcutaneous anchor securement system that is designed to secure both central venous catheters and peripherally inserted central catheters, SecurAcath is now used in more than 100 National Health Services facilities across England. However, until this new retrospective study, there has been little conclusive evidence on which securement methods actually prevent partial or complete dislodgement. Both McCormick and Hawes hope that the evidence from the new study will accelerate the adoption of SecurAcath, currently the only subcutaneous anchor securement system, reducing unplanned catheter removals, complications, and improving patient outcomes. They also expect that the increased use of the devices will bring significant cost savings, despite higher upfront costs, because only one device is required until the catheter is removed unlike all other engineered securement devices, including ASDs. Additionally, a secure catheter will lower hospital readmissions and reduce the need for multiple lines to complete therapy. Indeed, a review by an advisory committee of the UK's National Institute for Health and Care Excellence estimates annual savings at more than £4.2 million. The new retrospective study adds to a growing body of research showing benefits of subcutaneous anchor devices, including a 2020 study that showed reduced risk of bloodstream infections and a 2022 study that evaluated safety and efficacy outcomes for CVAD securement options. Hawes will present the new data at the October 14-17 Association for Vascular Access 2023 Annual Scientific Meeting, which will be held in Portland, Oregon. Her presentation, "Keep it Simple Specialist: One Securement Device, One PICC, Until the End of Need," will take place on Sunday, October 15 at 1 p.m. PDT. Source:
InterRad Medical Frequently Asked Questions (FAQ)
When was InterRad Medical founded?
InterRad Medical was founded in 2000.
Where is InterRad Medical's headquarters?
InterRad Medical's headquarters is located at 181 Cheshire Lane, Plymouth.
What is InterRad Medical's latest funding round?
InterRad Medical's latest funding round is Debt - III.
How much did InterRad Medical raise?
InterRad Medical raised a total of $31.57M.
Who are the investors of InterRad Medical?
Investors of InterRad Medical include National Health Service, Paycheck Protection Program, RBC Capital Partners, Arthurian Life Sciences and TGap Ventures.
Who are InterRad Medical's competitors?
Competitors of InterRad Medical include Avedro, Calibra Medical, SciBase, InaVein, Caliber Imaging & Diagnostics and 7 more.
Compare InterRad Medical to Competitors
CleveX Inc. is a medical device company that is developing and marketing skin biopsy closure and repair solutions for the dermatology cosmetic surgery and primary care physicians. CleveX (LLC) started out in 2004 as a joint venture between Cleveland Clinic Foundation (Cleveland OH) and IDx Medical Design (Cincinnati OH) to develop and commercialize surgical dermatology and skin repair innovations generated by leading physicians at the Cleveland Clinic. The company's lead technology platform is the ExiClip. The ExiClip is a single-step disposable surgical device that efficiently excises a skin lesion while simultaneously closing and repairing the surgical site.
Endologix is a company focused on the development and manufacturing of minimally invasive treatments for aortic disorders, operating within the medical devices industry. The company's main offerings include a variety of endovascular stent grafts, which are used for the treatment of abdominal aortic aneurysms (AAA), a condition characterized by a weakening of the wall of the aorta that can lead to a balloon-like enlargement. Endologix primarily serves the healthcare sector, particularly in areas related to vascular disease and aortic disorders. It was founded in 1992 and is based in Irvine, California.
PreMD Inc. is dedicated to saving and improving people's lives with simple, painless and patient-friendly tests that can detect life-threatening illnesses at a. The company's tests do not require any patient preparation or dietary restrictions and can be performed at the point of care, in a laboratory setting and, in some cases, even at home. The company's cardiovascular risk assessment technology, PREVU* Skin Sterol Test, assesses a patient's risk of heart disease by non-invasively measuring the amount of cholesterol in the skin tissues. PreMD's non- or minimally-invasive tests for early-stage colorectal, lung and breast cancers detect a cancer-associated sugar in a sample of rectal mucus, sputum and breast nipple aspirate fluid, respectively. The company's cancer tests are in development.
Navis is a Cleveland, Ohio based company that has developed the Variable Control Guidewire System, a guidewire technology that aims to improve endovascular navigation and eliminate or reduce the need for multiple catheters and guidewires required during invasive peripheral vascular procedures.
CryoPen is a developer and manufacturer of state-of-the art medical devices and aesthetic treatment systems. CryoPen is committed to delivering the most effective, and profitable solutions available to healthcare providers, physicians of all specialties, and medical spas. The company's product portfolio aims to enable physicians to provide a higher quality of care and offer their patients a more diverse array of treatments while generating a substantial revenue stream for their practice. CryoPen's product set addresses a multitude of treatment applications such as laser hair removal, skin rejuvenation, cryosurgery, cellulite reduction, vascular lesions, pigmented lesions, acne, psoriasis, fine lines & wrinkles, scar and tattoo removal, photo facials, and skin tightening. With a dedication to the research and development of technologically advanced devices and equipment, every CryoPen product is designed to create a better patient experience, consistent clinical outcomes, and economic impact on the bottom line of their practice.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.